홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Milbemycin D → HCID 101591932, 화합물

HRID 2081168
노트
인쇄 미리보기

반응식

HRID 2081168 반응식
C[C@@H]1[C@@H](C)O[C@]2([O:10][C@@H]3CC=C(C)C[C@@H](C)C=CC=C4CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(O[C@@H](C3)C2)=O)[C@]45O)CC1.[CH3:39][C@@H:40]1[C@@H:75]([CH:76]([CH3:78])[CH3:77])[O:74][C@:43]2([O:48][C@@H:47]3[CH2:49][CH:50]=[C:51]([CH3:73])[CH2:52][C@@H:53]([CH3:72])[CH:54]=[CH:55][CH:56]=[C:57]4[CH2:58][O:59][C@@H:60]5[C@H:65]([OH:66])[C:64]([CH3:67])=[CH:63][C@@H:62]([C:68]([O:70][C@@H:45]([CH2:46]3)[CH2:44]2)=[O:69])[C@:61]45[OH:71])[CH2:42][CH2:41]1.C[C@@H]1[C@@H](C)O[C@]2(O[C@@H]3CC=C(C)[C@H](O)[C@@H](C)C=CC=C4CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(O[C@@H](C3)C2)=O)[C@]45O)CC1>>[CH3:39][C@@H:40]1[C@@H:75]([CH:76]([CH3:78])[CH3:77])[O:74][C@:43]2([O:48][C@@H:47]3[CH2:49][CH:50]=[C:51]([CH3:73])[C@H:52]([OH:10])[C@@H:53]([CH3:72])[CH:54]=[CH:55][CH:56]=[C:57]4[CH2:58][O:59][C@@H:60]5[C@H:65]([OH:66])[C:64]([CH3:67])=[CH:63][C@@H:62]([C:68]([O:70][C@@H:45]([CH2:46]3)[CH2:44]2)=[O:69])[C@:61]45[OH:71])[CH2:42][CH2:41]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

4

반응물 3

HCID 6440579Milbemycin DHCID 9828343(6R,25R)-5-O-Demethyl-28-deoxy-6,28-epoxy-25-methylmilbemycin BHCID 101591931HCID 101591931, 화합물

생성물 1

HCID 101591932HCID 101591932, 화합물수율 29%

실험 절차

If milbemycin A3 or milbemycin D is reacted in an analogous manner, for example at a conversion rate of 10% a ratio of 40% 13β-hydroxymilbemycin A3 and 60% 14,15-epoxymilbemycin A3 is obtained or, at a conversion rate of 13%, a ratio of 29% 13β-hydroxymilbemycin D to 71% 14,15-epoxymilbemycin D is obtained (HPLC analysis).

후처리

  1. customis obtained or, at a conversion rate of 13%

출처 및 근거

ORD 기록
ord-489d187bbc95423ba9b500c2908563fb
출처 데이터셋
uspto-grants-1993_02
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US05183749

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트